Prescription Patterns of Osteoporosis Medications in Patients With Advanced CKD: A Retrospective Cohort Study

Ignacio A. Portales-Castillo; Cagri Aksu; Sophia Zhao; Ian Strohbehn; Meghan Sise; Elaine W. Yu; Sagar U. Nigwekar

doi:10.1016/j.xkme.2021.07.005

Prescription Patterns of Osteoporosis Medications in Patients With Advanced CKD: A Retrospective Cohort Study

Ignacio A. Portales-Castillo, Cagri Aksu, Sophia Zhao, Ian Strohbehn, Meghan Sise, Elaine W. Yu, Sagar U. Nigwekar

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1112-1115
Number of pages	4
Journal	Kidney Medicine
Volume	3
Issue number	6
DOIs	https://doi.org/10.1016/j.xkme.2021.07.005
State	Published - Nov 1 2021

Access to Document

10.1016/j.xkme.2021.07.005

Cite this

@article{2f4a12d5d517483da3616a3a70c0b02a,

title = "Prescription Patterns of Osteoporosis Medications in Patients With Advanced CKD: A Retrospective Cohort Study",

author = "Portales-Castillo, {Ignacio A.} and Cagri Aksu and Sophia Zhao and Ian Strohbehn and Meghan Sise and Yu, {Elaine W.} and Nigwekar, {Sagar U.}",

note = "Funding Information: Dr Nigwekar reports grant support from Hope Pharmaceuticals, Laboratories Sanifit, and Inozyme Pharma to his institute and honoraria from Fresenius Renal Therapies, Epizon Pharma, and Laboratoris Sanifit. Ms Sise reports no relevant disclosures. Dr Yu reports grant support from Amgen, Inc and Seres Therapeutics. Funding Information: Ignacio A. Portales-Castillo, MD, Cagri Aksu, MD, Sophia Zhao, MD, PhD, Ian Strohbehn, BA, Meghan Sise, MD, Elaine W. Yu, MD, and Sagar U. Nigwekar, MD, MMSc. Research idea and study design: IAP-C, SUN, EWY; data acquisition: IAP-C, CA; data analysis/interpretation: IAP-C, SUN, EWY, CA; SZ, IS, MS; statistical analysis: IAP-C, SZ; supervision or mentorship: SUN, EWY, MS. SUN and EWY contributed equally to research project oversight and thus serve as co-senior authors. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. None. Dr Nigwekar reports grant support from Hope Pharmaceuticals, Laboratories Sanifit, and Inozyme Pharma to his institute and honoraria from Fresenius Renal Therapies, Epizon Pharma, and Laboratoris Sanifit. Ms Sise reports no relevant disclosures. Dr Yu reports grant support from Amgen, Inc and Seres Therapeutics. Received May 21, 2021, as a submission to the expedited consideration track with 2 external peer reviews. Direct editorial input from the Statistical Editor and the Editor-in-Chief. Accepted in revised form July 11, 2021.",

year = "2021",

month = nov,

day = "1",

doi = "10.1016/j.xkme.2021.07.005",

language = "English",

volume = "3",

pages = "1112--1115",

journal = "Kidney Medicine",

issn = "2590-0595",

number = "6",

}

TY - JOUR

T1 - Prescription Patterns of Osteoporosis Medications in Patients With Advanced CKD

T2 - A Retrospective Cohort Study

AU - Portales-Castillo, Ignacio A.

AU - Aksu, Cagri

AU - Zhao, Sophia

AU - Strohbehn, Ian

AU - Sise, Meghan

AU - Yu, Elaine W.

AU - Nigwekar, Sagar U.

N1 - Funding Information: Dr Nigwekar reports grant support from Hope Pharmaceuticals, Laboratories Sanifit, and Inozyme Pharma to his institute and honoraria from Fresenius Renal Therapies, Epizon Pharma, and Laboratoris Sanifit. Ms Sise reports no relevant disclosures. Dr Yu reports grant support from Amgen, Inc and Seres Therapeutics. Funding Information: Ignacio A. Portales-Castillo, MD, Cagri Aksu, MD, Sophia Zhao, MD, PhD, Ian Strohbehn, BA, Meghan Sise, MD, Elaine W. Yu, MD, and Sagar U. Nigwekar, MD, MMSc. Research idea and study design: IAP-C, SUN, EWY; data acquisition: IAP-C, CA; data analysis/interpretation: IAP-C, SUN, EWY, CA; SZ, IS, MS; statistical analysis: IAP-C, SZ; supervision or mentorship: SUN, EWY, MS. SUN and EWY contributed equally to research project oversight and thus serve as co-senior authors. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. None. Dr Nigwekar reports grant support from Hope Pharmaceuticals, Laboratories Sanifit, and Inozyme Pharma to his institute and honoraria from Fresenius Renal Therapies, Epizon Pharma, and Laboratoris Sanifit. Ms Sise reports no relevant disclosures. Dr Yu reports grant support from Amgen, Inc and Seres Therapeutics. Received May 21, 2021, as a submission to the expedited consideration track with 2 external peer reviews. Direct editorial input from the Statistical Editor and the Editor-in-Chief. Accepted in revised form July 11, 2021.

PY - 2021/11/1

Y1 - 2021/11/1

UR - http://www.scopus.com/inward/record.url?scp=85120605248&partnerID=8YFLogxK

U2 - 10.1016/j.xkme.2021.07.005

DO - 10.1016/j.xkme.2021.07.005

M3 - Article

C2 - 34939026

AN - SCOPUS:85120605248

SN - 2590-0595

VL - 3

SP - 1112

EP - 1115

JO - Kidney Medicine

JF - Kidney Medicine

IS - 6

ER -

Prescription Patterns of Osteoporosis Medications in Patients With Advanced CKD: A Retrospective Cohort Study

Access to Document

Other files and links

Cite this